Therapeutic exploitation of the neonatal Fc receptor in albumin-based drug designs

The neonatal Fc receptor (FcRn) plays a pivotal role in maintaining the homeostasis of immunoglobulin G and human serum albumin by diversion from lysosomal degradation by a cellular recycling mechanism. Leveraging this function, FcRn has been targeted to utilize albumin as a delivery platform, aiming to prolong the half-life of associated drugs. As our understanding of the FcRn expression profile in health and disease and diverse functions expands, new therapeutic opportunities emerge. This chapter addresses FcRn interactions, functional roles, with utilization for albumin-based drug strategies. Furthermore, we propose future directions for harnessing FcRn in drug designs.